Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking method to diabetes management. These innovative drugs work by mimicking the physiological actions of GLP-1, a hormone secreted by the gut in response to consumption. By stimulating GLP-1 receptors in the pancreas, these substances enhance insulin production and reduce glu

Retaglutide and tirzepatide represent cutting-edge class of medications known as dual GLP-1 and GIP agonists. These agents target both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that play a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, these hormones are